Showing results (561-570 of 689) with videos related to
Sort By:
Pageof 69
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.Metabolic Brain Disease|June 27, 2016
Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS normsJasmohan S Bajaj, Melanie B White, Ariel B Unser, et al.International Journal of Clinical Practice|June 16, 2012
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional studyR Lencioni, M Kudo, S-L Ye, et al.Radiology|January 9, 2016
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEONJean-François Geschwind, Masatoshi Kudo, Jorge A Marrero, et al.Journal of Hepatology|July 30, 2016
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON studyJorge A Marrero, Masatoshi Kudo, Alan P Venook, et al.Nature Medicine|September 7, 2023
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitisArun J Sanyal, Sudha S Shankar, Katherine P Yates, et al.Hepatology (Baltimore, Md.)|January 16, 2023
Examining the interim proposal for name change to steatotic liver disease in the US populationCheng Han Ng, Kai En Chan, Mark Muthiah, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 4, 2024
AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory studyHai-Yang Yuan, Xiao-Fei Tong, Ya-Yun Ren, et al.The Lancet. Oncology|March 7, 2022
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysisDarren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.Pageof 69